Please login to the form below

Not currently logged in
Email:
Password:

Entyvio

This page shows the latest Entyvio news and features for those working in and with pharma, biotech and healthcare.

Modest meeting sees only two drugs recommended by CHMP

Modest meeting sees only two drugs recommended by CHMP

Takeda also picked up a positive recommendation for a new subcutaneous formulation of its ulcerative colitis and Crohn’s med Entyvio (vedolizumab).

Latest news

More from news
Approximately 8 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Gut instincts lead Takeda to GI pipeline success Gut instincts lead Takeda to GI pipeline success

    Millennium Pharmaceuticals for $8.8bn, when he was part of the team developing Entyvio. ... The buzz was that Entyvio wouldn’t make it and there were tremendous challenges, but the uniqueness of its mode of action kept us going.”.

  • Forging a path in specialty care Forging a path in specialty care

    Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA ... The best example is Entyvio. It

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics